FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: A prospective study (original) (raw)

FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer

Arie Figer

Cancer, 2007

View PDFchevron_right

Comparative Effectiveness of Chemotherapy in Elderly Patients with Metastatic Colorectal Cancer

Carolina Reyes, Edward McKenna

Journal of Gastrointestinal Cancer, 2012

View PDFchevron_right

Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer

A. Grothey, Axel Hinke

Clinical Colorectal Cancer, 2008

View PDFchevron_right

Safe Use of FOLFOX in Two Patients With Metastatic Colorectal Carcinoma and Severe Hepatic Dysfunction

Jhenee Bubenzer

Clinical Colorectal Cancer, 2011

View PDFchevron_right

Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: Final results of the Southern Italy Cooperative Oncology Group Trial 0108

vito lorusso

Cancer, 2005

View PDFchevron_right

Toxicities and Survival Among Octogenarians and Nonagenarians with Colorectal Cancer Treated with Chemotherapy or Concurrent Chemoradiation Therapy

Marwan Fakih

Clinical Colorectal Cancer, 2007

View PDFchevron_right

Effects of newly developed chemotherapy regimens, comorbidities, chemotherapy-related toxicities on the changing patterns of the leading causes of death in elderly patients with colorectal cancer

Dejian Lai

Annals of Oncology, 2014

View PDFchevron_right

Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial

Giuseppe Tonini

ESMO Open, 2017

View PDFchevron_right

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

Francesca Battaglin

BMC cancer, 2018

View PDFchevron_right

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

Matthew Seymour

The Lancet, 2011

View PDFchevron_right

Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse

eghon guzman

ecancermedicalscience, 2019

View PDFchevron_right

Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer

Edoardo Francini

Clinical Colorectal Cancer, 2018

View PDFchevron_right

Elderly patients with colorectal cancer: Treatment modalities and survival in France. National data from the ThInDiT cohort study

Philippe Ricordeau

European Journal of Cancer, 2014

View PDFchevron_right

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

Alfredo Carrato

Drugs & Aging, 2021

View PDFchevron_right

Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG)

A. Karampeazis, Athanasios Athanasiadis

Critical Reviews in Oncology/Hematology, 2010

View PDFchevron_right

A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis

Seok Jae Huh

Cancer Research and Treatment, 2011

View PDFchevron_right

Chemotherapy for older patients with colorectal cancer

Matthew Seymour

The Lancet, 2011

View PDFchevron_right

5-Fluorouracil–Based Chemotherapy for Advanced Colorectal Cancer in Elderly Patients: A North Central Cancer Treatment Group Study

Daniel Sargent

Clinical Colorectal Cancer, 2005

View PDFchevron_right

Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review)

Lubomir Bodnar

Oncology Letters, 2010

View PDFchevron_right

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study

Nikolaos Androulakis

BMC Cancer, 2007

View PDFchevron_right

Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma

Donato Natale

Cancer, 2005

View PDFchevron_right

Efficacy and Tolerability of Chemotherapy in Elderly Patients with Metastatic Gastric Cancer

Melih Simsek

Turkish Journal of Geriatrics-Turk Geriatri Dergisi, 2016

View PDFchevron_right

Do we know what to do with our nonagenarian and centenarian patients with metastatic colorectal cancer (mCRC)? Results from the South Australian mCRC registry

AMITESH Roy

Acta oncologica (Stockholm, Sweden), 2018

View PDFchevron_right

Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG)

Nikolaos Kentepozidis

Journal of Geriatric Oncology, 2019

View PDFchevron_right

Chemotherapy in Elderly Patients with Metastatic Colorectal Cancer: Relations to Co-morbidities and Functional abilities

Loaie El-Helw

View PDFchevron_right

FOLFOX (oxaliplatin and 5fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study

Mohammad Hassan

Indian Journal of Cancer, 2011

View PDFchevron_right

FOLFOX-4 Regimen as First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer: A Safety Study

rocco giannicola

Journal of Chemotherapy, 2007

View PDFchevron_right

Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used?

Theofanis Economopoulos

Acta Oncologica, 2012

View PDFchevron_right

Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer

Mireia Gil Raga

Journal of Clinical Medicine

View PDFchevron_right

FOLFOX Alternated with FOLFIRI as First-Line Chemotherapy for Metastatic Colorectal Cancer

Jorge Aparicio

Clinical Colorectal Cancer, 2005

View PDFchevron_right

Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis

Lubomir Bodnar

Journal of Cancer Research and Clinical Oncology, 2010

View PDFchevron_right